NEW YORK (GenomeWeb News) — Gene Logic today said it will help Solvay Pharmaceuticals identify alternative development paths for multiple undisclosed drug candidates.
 
All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.
 
Terms of the deal call for Gene Logic to pocket milestone and royalty payments similar to those paid for development-stage in-licensing deals, discounted for the fact that Solvay originally identified the compounds.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.